Abstract
Acute myeloid leukemia (AML) is a malignant disease of the bone marrow. Despite intensive treatment only one third of AML patients are cured. Numerous genetic events have been identified in the last years that have shed light into the mechanisms dictating increased self-renewal, proliferation, survival and block in differentiation. It is increasingly recognized that AML represents a hierarchical disease, originating from a leukemia stem cell population. Sophisticated animal models have helped to elucidate rate-limiting steps in initiation, development and maintenance of AML. This review discusses the fundamental genetic events identified to date that determine the pathogenesis of AML, with particular emphasis on the oncogenic signaling events that result from translocation of myeloid transcription factors and mutations in receptor tyrosine kinases. Our current understanding of the biology of AML has fueled the development of promising anti-leukemic agents, which may improve the treatment of the disease in the future.
Keywords: Acute promyelocytic leukemia (APL), core binding factor (CBF), GATA-1 mutation, Nucleophosmin (NPM), MLL protein, Hox homeodomain proteins
Current Drug Targets
Title: Oncogenic Signaling in Acute Myeloid Leukemia
Volume: 8 Issue: 2
Author(s): Christian H. Brandts, Wolfgang E. Berdel and Hubert Serve
Affiliation:
Keywords: Acute promyelocytic leukemia (APL), core binding factor (CBF), GATA-1 mutation, Nucleophosmin (NPM), MLL protein, Hox homeodomain proteins
Abstract: Acute myeloid leukemia (AML) is a malignant disease of the bone marrow. Despite intensive treatment only one third of AML patients are cured. Numerous genetic events have been identified in the last years that have shed light into the mechanisms dictating increased self-renewal, proliferation, survival and block in differentiation. It is increasingly recognized that AML represents a hierarchical disease, originating from a leukemia stem cell population. Sophisticated animal models have helped to elucidate rate-limiting steps in initiation, development and maintenance of AML. This review discusses the fundamental genetic events identified to date that determine the pathogenesis of AML, with particular emphasis on the oncogenic signaling events that result from translocation of myeloid transcription factors and mutations in receptor tyrosine kinases. Our current understanding of the biology of AML has fueled the development of promising anti-leukemic agents, which may improve the treatment of the disease in the future.
Export Options
About this article
Cite this article as:
Brandts H. Christian, Berdel E. Wolfgang and Serve Hubert, Oncogenic Signaling in Acute Myeloid Leukemia, Current Drug Targets 2007; 8 (2) . https://dx.doi.org/10.2174/138945007779940197
DOI https://dx.doi.org/10.2174/138945007779940197 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Bioactive as a Potential Therapeutic Approach for the Management of Cyclophosphamide-induced Cardiotoxicity
Current Topics in Medicinal Chemistry A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma
Current Topics in Medicinal Chemistry Mast Cell Disorders In Drug Hypersensitivity
Current Pharmaceutical Design Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges
Current Topics in Medicinal Chemistry Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Patents and the Development on Polymer based Nanomaterial (PAMAM Dendrimer) for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued) Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy A Review of Fish Lectins
Current Protein & Peptide Science Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Molecular Approaches to Cervical Cancer Therapy
Current Drug Discovery Technologies Magnetic Resonance Imaging of Uncommon Hepatic Mesenchymal Tumours: Haemangioendothelioma and Angiosarcoma
Current Medical Imaging YB-1 Activities in Oncogenesis: Transcription and Translation
Current Cancer Therapy Reviews Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers
Current Topics in Medicinal Chemistry Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets